文献速递神经免疫神经肌肉病

免疫检查点抑制剂相关的颅神经疾病

Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors.
PubMed 文献 · Neurology · 2020-12-14

本研究通过法国参考中心2015-2019年全国回顾性队列(9例)及2010-2019年文献系统综述(共39例)描述免疫检查点抑制剂相关颅神经疾病(Cn-ICI)的谱系、治疗与结局。Cn-ICI可累及视神经、前庭蜗神经、展神经、面神经和动眼神经等,约三分之一患者遗留或加重神经功能缺损,最常见为听力与视力丧失。

要点

  • Cn-ICI可累及视神经、前庭蜗神经、展神经、面神经和动眼神经,部分患者多颅神经受累。
  • 治疗以糖皮质激素为主,多数患者永久停用ICI,部分接受血浆置换或IVIG。
  • 约三分之一患者神经功能缺损持续或加重,以视力和听力损害最常见。

核心结论

  • 颅神经疾病可并发于免疫检查点抑制剂治疗,约三分之一患者遗留神经功能缺损,最常见为听力与视力丧失。

研究设计与样本

  • 法国参考中心2015-2019年全国回顾性队列研究,纳入67例ICI相关神经毒性中的9例Cn-ICI患者。
  • 按PRISMA指南系统检索MEDLINE、Scopus和Web of Science(2010-2019年)文献,与本研究系列合并共39例。

主要发现

  • 本中心9例Cn-ICI患者中位年龄62岁(范围26-82岁),男性7例(78%)。
  • 本中心9例中受累神经包括视神经3例、前庭蜗神经3例、展神经2例、面神经2例、动眼神经1例,2例累及2条不同颅神经。
  • 本中心9例中治疗包括糖皮质激素8例(89%)、永久停用ICI 7例(78%)、血浆置换2例(22%)、IVIG 1例(11%),中位随访11个月(范围1-41个月)。
  • 本中心9例中3例(33%)神经功能缺损持续或加重,分别为2例视神经和1例前庭蜗神经。
  • 合并39例中最常受累颅神经为面神经13例(33%)、前庭蜗神经8例(21%)、视神经7例(18%)、展神经4例(10%),三叉、动眼和舌咽神经共7例。

临床怎么用

  • 接受ICI治疗的患者出现颅神经症状时,应警惕Cn-ICI并及时识别。
  • 多数Cn-ICI患者需永久停用ICI并接受糖皮质激素治疗,部分可考虑血浆置换或IVIG。
  • 视神经和前庭蜗神经受累者可能遗留持久功能障碍,需密切随访。

局限性

  • 本研究为回顾性队列,样本量小(本中心9例,合并39例)。
  • 文献综述仅纳入2010-2019年发表记录,可能存在发表偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the spectrum, treatment, and outcome of cranial nerve disorders associated with immune checkpoint inhibitor (Cn-ICI). METHODS: This nationwide retrospective cohort study on Cn-ICI (2015-2019) was conducted using the database of the French Refence Center. In addition, a systematic review of the literature (MEDLINE, Scopus, and Web of Science) for records published between 2010 and 2019 was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the search terms cranial nerve or neuropathy or palsy and immune checkpoint inhibitors. RESULTS: Among 67 cases with ICI-related neurologic toxicities diagnosed in our reference center, 9 patients with Cn-ICI were identified (7 men, 78%, median age 62 years [range 26-82 years]). Patients were receiving a combination of anti-cytotoxic T-lymphocyte antigen 4 and anti-programmed cell death 1 (PD-1)/PD-1 ligand (n = 5, 56%) or anti-PD-1 antibodies alone (n = 4, 44%). Cn-ICI involved optic (n = 3), vestibulocochlear (n = 3), abducens (n = 2), facial (n = 2), and oculomotor (n = 1) nerves. Two patients had involvement of 2 different cranial nerves. Treatment comprised corticosteroids (n = 8, 89%), ICI permanent discontinuation (n = 7, 78%), plasma exchange (n = 2, 22%), and IV immunoglobulin (n = 1, 11%). Median follow-up was 11 months (range 1-41 months). In 3 cases (33%), neurologic deficit persisted/worsened despite treatment: 2 optic and 1 vestibulocochlear. Among cases from the literature and the present series combined (n = 39), the most commonly affected cranial nerves were facial (n = 13, 33%), vestibulocochlear (n = 8, 21%), optic (n = 7, 18%), and abducens (n = 4, 10%). Trigeminal, oculomotor, and glossopharyngeal nerves were less frequently affected (total n = 7). CONCLUSION: Cranial nerve disorders can complicate treatment with ICIs. Approximately one-third of the patients had persisting deficits, most frequently involving hearing and vision loss.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Vogrig A, Muñiz-Castrillo S, Joubert B, et al. Cranial Nerve Disorders Associated With Immune Checkpoint Inhibitors. Neurology. 2020. PMID: 33318162. doi:10.1212/WNL.0000000000011340

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。